Eli Lilly Shares Face a Crucial Test After Stellar Run

Eli Lilly US5324571083

The remarkable ascent of Eli Lilly’s stock has hit a potential stumbling block. Following months of impressive gains, the equity has shown its first significant signs of weakness, retreating 6% over just a few trading sessions. This pullback interrupts what had seemed an unstoppable upward trajectory, leaving market participants to ponder a critical juncture: is this the end of the rally, or merely a healthy consolidation?